National Institute of Allergy and Infectious Diseases (NIAID)

FLC Region

Security Lab

No

Address

Technology Transfer and Intellectual Property Office
5601 Fishers Lane
Bethesda, MD 20892-9804
United States

Laboratory Representative

Description

The National Institute of Allergy and Infectious Diseases (NIAID) conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases. For more than 50 years, NIAID research has led to new therapies, vaccines, diagnostic tests, and other technologies that have improved the health of millions of people in the United States and around the world.

Tech Areas

Available Technologies
Displaying 61 - 70 of 190
Enhanced Immune Response Against Influenza Virus by Priming with a DNA-based Vaccine
Enhanced Tissue Clearing Solution, Clearing-Enhanced 3D (Ce3D), Compatible with Advanced Fluorescence Microscopy Imaging
Enhanced, Targeted Delivery for DNA Vaccines
Enhanced, Targeted Delivery for DNA Vaccines
Full-Length cDNA Clone Representing the Consensus Sequence of the RNA Genome of a Human Norovirus (strain MD145-12) That Encodes Biologically Active Proteins
Functional Promoter For CCR5
Glucocorticoid-induced TNFR Family-Related Receptor Ligand (GITRL) Antibodies for Diagnosis and Treatment of Immune System Disorders
HIV gp41-Membrane Proximal External Region Arrayed on Hepatitis B Surface Antigen Particles for HIV Diagnostic and Vaccine Applications
HPV Virus-Like Particles for Delivery of Gene-Based Vaccines
HPV Virus-Like Particles for Delivery of Gene-Based Vaccines

Pages

Funding

New Direct-to-SBIR Phase II Funding Award for NIAID Intramural Diagnostic Inventions

The National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), is pleased to announce the first NIAID Small Business Innovation Research-Technology Transfer (SBIR-TT) Direct-to-Phase II awards to move commercially viable diagnostic technologiesfrom NIAID intramural research laboratories into the marketplace. Direct-to-Phase II awards of up to $2M allow small businesses to compete even if they did not receive a Phase I SBIR award for research in the same area. An SBIR Phase II research and development plan tests the viability of the technology scientifically as well as its potential for commercialization. This Funding Opportunity Announcement (FOA)offers 18 diagnostic inventions for further development by small businesses. The list includes technologies related to hepatitis, cancer, tropical diseases, as well as other areas. As the lead federal organization conducting and supporting scientific research on infectious and immunologic diseases, NIAID carries out basic, applied, and clinicalinvestigations within intramurallaboratories and provides extramural grant, cooperative agreement, and contractsupport to research scientists worldwide. Any project that fits within the NIAID mission and relies on the use of the NIAID'u s intramural technologieslisted is eligible for this award.

Please contact Dr. Haiqing Li to discuss NIAID inventions. See FOA: NIAID SBIR - Technology Transfer Direct Phase II (SBIR-TT) (R44) for the details on eligibility and applying, or see the FAQ page for additional information.

No Programs for this lab
Facilities
Displaying 1 - 3 of 3
NIAID Core Facilities (Various)
Office of Chief Scientist, Integrated Research Facility (OCSIRF)
Rocky Mountain Laboratories (RML)
No Equipment for this lab
No publications for this lab
No awards for this lab
No news for this lab
Submit an Article
No success stories for this lab
Submit an Success Story